全文获取类型
收费全文 | 971篇 |
免费 | 74篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 38篇 |
妇产科学 | 5篇 |
基础医学 | 89篇 |
口腔科学 | 34篇 |
临床医学 | 86篇 |
内科学 | 241篇 |
皮肤病学 | 23篇 |
神经病学 | 36篇 |
特种医学 | 153篇 |
外科学 | 127篇 |
综合类 | 83篇 |
预防医学 | 39篇 |
药学 | 45篇 |
1篇 | |
肿瘤学 | 52篇 |
出版年
2021年 | 7篇 |
2020年 | 6篇 |
2019年 | 9篇 |
2018年 | 18篇 |
2017年 | 8篇 |
2016年 | 12篇 |
2015年 | 18篇 |
2014年 | 18篇 |
2013年 | 20篇 |
2012年 | 24篇 |
2011年 | 18篇 |
2010年 | 26篇 |
2009年 | 32篇 |
2008年 | 27篇 |
2007年 | 28篇 |
2006年 | 49篇 |
2005年 | 19篇 |
2004年 | 18篇 |
2003年 | 23篇 |
2002年 | 20篇 |
2001年 | 18篇 |
2000年 | 16篇 |
1999年 | 25篇 |
1998年 | 35篇 |
1997年 | 56篇 |
1996年 | 48篇 |
1995年 | 35篇 |
1994年 | 39篇 |
1993年 | 37篇 |
1992年 | 32篇 |
1991年 | 16篇 |
1990年 | 21篇 |
1989年 | 17篇 |
1988年 | 22篇 |
1987年 | 18篇 |
1986年 | 12篇 |
1985年 | 17篇 |
1984年 | 14篇 |
1983年 | 24篇 |
1982年 | 21篇 |
1981年 | 23篇 |
1980年 | 11篇 |
1979年 | 11篇 |
1978年 | 10篇 |
1977年 | 11篇 |
1976年 | 21篇 |
1975年 | 11篇 |
1974年 | 6篇 |
1973年 | 8篇 |
1970年 | 4篇 |
排序方式: 共有1054条查询结果,搜索用时 0 毫秒
101.
Chronic myelocytic leukemia (CML) may display a lymphoproliferative phase (lymphoid blast crisis) that is generally of B cell phenotype. Since lymphoproliferative disorders may occur following bone marrow transplantation (BMT), it may be difficult to distinguish posttransplant relapse of CML lymphoid blast crisis from de novo lymphoproliferation. Lymphoid blast crisis cells from a patient with CML displayed immunoglobulin heavy chain gene (C mu) rearrangement before BMT. Following BMT the patient developed a lymphoproliferative disorder involving multiple organs. Clonal rearrangement of C mu was demonstrated in several involved tissues. The rearranged C mu restriction fragment was distinct from that displayed before BMT. Additionally, rearrangement of the breakpoint cluster region (bcr) was demonstrated in the pretransplant blast crisis sample, but not in the posttransplant lymphoproliferation samples, thus confirming that these lymphoproliferative disorders were distinct. Molecular genetic techniques offer powerful diagnostic tools for monitoring the course of patients with CML undergoing BMT. 相似文献
102.
103.
104.
Red blood cell (RBC) protein 4.2 deficiency is often associated with a moderate nonimmune hemolytic anemia, splenomegaly, and osmotically fragile RBCs resembling, but not identical to, hereditary spherocytosis (HS). In the Japanese type of protein 4.2 deficiency (protein 4.2Nippon), the anemia is associated with a point mutation in the protein 4.2 cDNA. In this report, we describe a patient with moderate and apparently episodic nonimmune hemolytic anemia with splenomegaly, spherocytosis, osmotically fragile RBCs, reduced whole cell deformability, and abnormally dense cells. Sodium dodecyl sulfate- polyacrylamide gel electrophoresis analysis of the proposita's RBC membrane proteins showed an 88% deficiency of protein 4.2 and a 30% deficiency of glyceraldehyde-3-phosphate dehydrogenase (band 6). Structural and molecular analyses of the proposita's protein 4.2 were normal. In contrast, limited tryptic digestion of the proposita's band 3 showed a homozygous abnormality in the cytoplasmic domain. Analysis of the pedigree disclosed six members who were heterozygotes for the band 3 structural abnormality and one member who was a normal homozygote. Direct sequence analysis of the abnormal band 3 tryptic peptide suggested that the structural abnormality resided at or near residue 40. Sequence analysis of the proposita's band 3 cDNA showed a 232G-->A mutation resulting in a 40glutamic acid-->lysine substitution (band 3Montefiore). Allele-specific oligonucleotide hybridization was used to probe for the mutation in the pedigree, showing that the proposita was homozygous, and the pedigree members who were heterozygous for the band 3 structural abnormality were also heterozygous for the band 3Montefiore mutation. The band 3Montefiore mutation was absent in 26 chromosomes from race-matched controls and in one pedigree member who did not express the band 3 structural abnormality. In coincidence with splenectomy, the proposita's anemia was largely corrected along with the disappearance of most spherocytes and considerable improvements of RBC osmotic fragility, whole cell deformability, and cell density. We conclude that this hereditary hemolytic anemia is associated with the homozygous state for band 3Montefiore (40glutamic acid-->lysine) and a decreased RBC membrane content of protein 4.2. We speculate that band 3 structural abnormalities can result in defective interactions with protein 4.2 and band 6, and in particular, that the region of band 3 containing 40glutamic acid is involved directly or indirectly in interactions with these proteins. 相似文献
105.
Chang Yi Wang Lynette S. W. Sawyer Krishna K. Murthy Xinde Fang Alan M. Walfield John Ye James J. G. Wang Pei De Chen Ming Lie Li Mary T. Salas Ming Shen Marie-Claire Gauduin Rosanne W. Boyle Richard A. Koup David C. Montefiori John R. Mascola Wayne C. Koff Carl V. Hanson 《Proceedings of the National Academy of Sciences of the United States of America》1999,96(18):10367-10372
mAb B4 is a monoclonal antibody directed against HIV receptor complex. The antibody had broad neutralizing activity against HIV and provided postexposure prophylaxis to hu-peripheral blood leukocyte (PBL)-severe combined immunodeficient mice and chimpanzees. B4 recognized a complex receptor site for HIV on the T cell surface that includes CD4 and also may be influenced by interaction with HIV coreceptors. mAb B4 preferentially neutralized primary HIV-1 isolates compared with T cell line-adapted strains, including syncytium-inducing and non-syncytium-inducing phenotypes, representatives from HIV-1 subtypes A-G, as well as HIV-2, simian immunodeficiency virus, and chimeric simian/human immunodeficiency virus (SHIV). Neutralization was demonstrated in both pre- and postinfection models. The administration of mAb B4 after infectious challenge totally interrupted the infection of hu-PBL-severe combined immunodeficient mice by PBL-grown HIV-1 and the infection of chimpanzees by chimp-adapted HIV-1. This mode of protection suggested that the anti-HIV receptor antibody is efficacious for prophylaxis after exposure to HIV and for prevention of maternal transmission and may be an effective antiretroviral agent for treatment. 相似文献
106.
107.
108.
109.
110.